Appia Bio Announces Appointment of Irving Weissman, MD, and Mark Exley, PhD, to Scientific Advisory Board

LOS ANGELES: LOS ANGELES, Dec. 2, 2021 /PRNewswire/ -- Appia Bio, Inc., an early stage biotechnology company developing engineered allogeneic cell therapies from hematopoietic stem cells (HSCs) for cancer patients, today announced the appointment of Irving Weissman, MD, and Mark Exley, PhD, to its Scientific Advisory Board. Drs. Weissman and...

Click to view original post